Translating the ‘Sugar Code’ into Immune and Vascular Signaling Programs

Trends in Biochemical Sciences

Volumn 42, Issue 4, 2017, Pages 255-273

  Cerliani, Juan P ^a   Blidner, Ada G ^a   Toscano, Marta A ^a   Croci, Diego O ^a,b   Rabinovich, Gabriel A ^a,c  

^a Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

endothelial cells; galectins; glycans; lymphoid cells; myeloid cells

Indexed keywords

BINDING PROTEIN; GALECTIN; GLYCAN; GLYCAN BINDING PROTEIN; UNCLASSIFIED DRUG; POLYSACCHARIDE;

B LYMPHOCYTE; BONE MARROW; CARBOHYDRATE ANALYSIS; CARDIOVASCULAR SYSTEM; CELL FUNCTION; DENDRITIC CELL; ENDOCYTOSIS; ENDOTHELIUM; EOSINOPHIL; GENETIC ENGINEERING; HUMAN; IMMUNE SYSTEM; LYMPHOID TISSUE; MACROPHAGE; MAST CELL; MICROGLIA; MODEL; MOLECULAR INTERACTION; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; ORGANISM MODEL; PROTEIN AGGREGATION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; CHEMISTRY; IMMUNOLOGY; METABOLISM;

ENDOTHELIUM; GALECTINS; HUMANS; IMMUNE SYSTEM; POLYSACCHARIDES; SIGNAL TRANSDUCTION;

EID: 85008226080     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2016.11.003     Document Type: Review

References (167)

1. 1 Ohtsubo, K., Marth, J.D., Glycosylation in cellular mechanisms of health and disease. Cell 126 (2006), 855–867.
2. 2 Bard, F., et al. Cracking the glycome encoder: signaling, trafficking, and glycosylation. Trends Cell Biol. 26 (2016), 379–388.
3. 3 Moremen, K.W., et al. Vertebrate protein glycosylation: diversity, synthesis and function. Nat. Rev. Mol. Cell Biol. 13 (2012), 448–462.
4. 4 Pinho, S.S., Reis, C.A., Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer 15 (2015), 540–555.
5. 5 Albrecht, S., et al. Glycosylation as a marker for inflammatory arthritis. Cancer Biomark. 14 (2014), 17–28.
6. 6 Johnson, J.L., et al. The regulatory power of glycans and their binding partners in immunity. Trends Immunol. 34 (2013), 290–298.
7. 7 Rabinovich, G.A., Croci, D.O., Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 36 (2012), 322–335.
8. 8 Rabinovich, G.A., Toscano, M.A., Turning ‘sweet’ on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol. 9 (2009), 338–352.
9. 9 Nabi, I.R., et al. The galectin lattice at a glance. J. Cell Sci. 128 (2015), 2213–2219.
10. 10 Demetriou, M., et al. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409 (2001), 733–739.
11. 11 Bonzi, J., et al. Pre-B cell receptor binding to galectin-1 modifies galectin-1/carbohydrate affinity to modulate specific galectin-1/glycan lattice interactions. Nat. Commun., 6, 2015, 6194.
12. 12 Partridge, E.A., et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306 (2004), 120–124.
13. 13 Starossom, S.C., et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity 37 (2012), 249–263.
14. 14 Kouo, T., et al. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol. Res. 3 (2015), 412–423.
15. 15 Lau, K.S., et al. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 129 (2007), 123–134.
16. 16 Zhu, C., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6 (2005), 1245–1252.
17. 17 Rangachari, M., et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat. Med. 18 (2012), 1394–1400.
18. 18 Croci, D.O., et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 156 (2014), 744–758.
19. 19 Markowska, A.I., et al. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J. Biol. Chem. 286 (2011), 29913–29921.
20. 20 Chen, W.S., et al. Pathological lymphangiogenesis is modulated by galectin-8-dependent crosstalk between podoplanin and integrin-associated VEGFR–3. Nat. Commun., 7, 2016, 11302.
21. 21 Motz, G.T., Coukos, G., The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 11 (2011), 702–711.
22. 22 Rabinovich, G.A., et al. Activated rat macrophages produce a galectin-1-like protein that induces apoptosis of T cells: biochemical and functional characterization. J. Immunol. 160 (1998), 4831–4840.
23. 23 Sato, S., Hughes, R.C., Control of Mac-2 surface expression on murine macrophage cell lines. Eur. J. Immunol. 24 (1994), 216–221.
24. 24 Barrionuevo, P., et al. A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway. J. Immunol. 178 (2007), 436–445.
25. 25 Correa, S.G., et al. Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages. Glycobiology 13 (2003), 119–128.
26. 26 Zuniga, E., et al. Regulated expression and effect of galectin-1 on Trypanosoma cruzi-infected macrophages: modulation of microbicidal activity and survival. Infect. Immun. 69 (2001), 6804–6812.
27. 27 Rostoker, R., et al. Galectin-1 induces 12/15-lipoxygenase expression in murine macrophages and favors their conversion toward a pro-resolving phenotype. Prostaglandin other Lipid Mediat. 107 (2013), 85–94.
28. 28 Malik, R.K., et al. Galectin-1 stimulates monocyte chemotaxis via the p44/42 MAP kinase pathway and a pertussis toxin-sensitive pathway. Glycobiology 19 (2009), 1402–1407.
29. 29 Sano, H., et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J. Immunol. 165 (2000), 2156–2164.
30. 30 Sano, H., et al. Critical role of galectin-3 in phagocytosis by macrophages. J. Clin. Invest. 112 (2003), 389–397.
31. 31 Yamaoka, A., et al. A human lectin, galectin-3 (epsilon bp/Mac-2), stimulates superoxide production by neutrophils. J. Immunol. 154 (1995), 3479–3487.
32. 32 Hsu, D.K., et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am. J. Pathol. 156 (2000), 1073–1083.
33. 33 Jeon, S.B., et al. Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. J. Immunol. 185 (2010), 7037–7046.
34. 34 Lalancette-Hebert, M., et al. Galectin-3 is required for resident microglia activation and proliferation in response to ischemic injury. J. Neurosci. 32 (2012), 10383–10395.
35. 35 Burguillos, M.A., et al. Microglia-secreted galectin-3 acts as a Toll-like Receptor 4 ligand and contributes to microglial activation. Cell Rep. 10 (2015), 1626–1638.
36. 36 Hoyos, H.C., et al. Galectin-3 controls the response of microglial cells to limit cuprizone-induced demyelination. Neurobiol. Dis. 62 (2014), 441–455.
37. 37 MacKinnon, A.C., et al. Regulation of alternative macrophage activation by galectin-3. J. Immunol. 180 (2008), 2650–2658.
38. 38 Jia, W., et al. Galectin-3 accelerates M2 macrophage infiltration and angiogenesis in tumors. Am. J. Pathol. 182 (2013), 1821–1831.
39. 39 Yildirim, C., et al. Galectin-2 induces a proinflammatory, anti-arteriogenic phenotype in monocytes and macrophages. PLoS ONE, 10, 2015, e0124347.
40. 40 Jayaraman, P., et al. Tim-3 binding to galectin-9 stimulates antimicrobial immunity. J. Exp. Med. 207 (2010), 2343–2354.
41. 41 Sada-Ovalle, I., et al. The Tim-3-galectin 9 pathway induces antibacterial activity in human macrophages infected with Mycobacterium tuberculosis. J. Immunol. 12 (2012), 5896–5902.
42. 42 Anderson, A.C., et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 318 (2007), 1141–1143.
43. 43 Ma, C.J., et al. Cis association of galectin-9 with Tim-3 differentially regulates IL-12/IL-23 expressions in monocytes via TLR signaling. PLoS ONE, 8, 2013, e72488.
44. 44 Vaitaitis, G.M., Wagner, D.H. Jr, Galectin-9 controls CD40 signaling through a Tim-3 independent mechanism and redirects the cytokine profile of pathogenic T cells in autoimmunity. PLoS ONE, 7, 2012, e38708.
45. 45 Leitner, J., et al. TIM-3 does not act as a receptor for galectin-9. PLoS Pathog., 9, 2013, e1003253.
46. 46 Wan, L., et al. Galectin-12 enhances inflammation by promoting M1 polarization of macrophages and reduces insulin sensitivity in adipocytes. Glycobiology 7 (2016), 732–744.
47. 47 Bax, M., et al. Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by siglecs and galectins. J. Immunol. 179 (2007), 8216–8224.
48. 48 Ilarregui, J.M., et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 10 (2009), 981–991.
49. 49 Mari, E.R., et al. Galectin-1 is essential for the induction of MOG35-55 -based intravenous tolerance in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 46 (2016), 1783–1796.
50. 50 Blois, S.M., et al. A pivotal role for galectin-1 in fetomaternal tolerance. Nat. Med. 13 (2007), 1450–1457.
51. 51 Poncini, C.V., et al. Trypanosoma cruzi Infection Imparts a regulatory program in dendritic cells and T cells via galectin-1-dependent mechanisms. J. Immunol. 195 (2015), 3311–3324.
52. 52 Mobergslien, A., Sioud, M., Galectin-1 and -3 gene silencing in immature and mature dendritic cells enhances T cell activation and interferon-gamma production. J. Leukoc. Biol. 91 (2012), 461–467.
53. 53 Fulcher, J.A., et al. Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling. J. Biol. Chem. 284 (2009), 26860–26870.
54. 54 Thiemann, S., et al. Galectin-1 regulates tissue exit of specific dendritic cell populations. J. Biol. Chem. 290 (2015), 22662–22677.
55. 55 Tesone, A.J., et al. Satb1 overexpression drives tumor-promoting activities in cancer-associated dendritic cells. Cell Rep. 14 (2016), 1774–1786.
56. 56 Kuo, P.L., et al. Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor. J. Biol. Chem. 287 (2012), 9753–9764.
57. 57 Fermin Lee, A., et al. Galectin-3 modulates Th17 responses by regulating dendritic cell cytokines. Am. J. Pathol. 183 (2013), 1209–1222.
58. 58 Fermino, M.L., et al. Lack of galectin-3 increases Jagged1/Notch activation in bone marrow-derived dendritic cells and promotes dysregulation of T helper cell polarization. Mol. Immunol. 76 (2016), 22–34.
59. 59 Breuilh, L., et al. Galectin-3 modulates immune and inflammatory responses during helminthic infection: impact of galectin-3 deficiency on the functions of dendritic cells. Infect. Immun. 75 (2007), 5148–5157.
60. 60 Volarevic, V., et al. Gal-3 regulates the capacity of dendritic cells to promote NKT-cell-induced liver injury. Eur. J. Immunol. 45 (2015), 531–543.
61. 61 Hsu, D.K., et al. Endogenous galectin-3 is localized in membrane lipid rafts and regulates migration of dendritic cells. J. Invest. Dermatol. 129 (2009), 573–583.
62. 62 Shan, M., et al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science 342 (2013), 447–453.
63. 63 Dai, S.Y., et al. Galectin-9 induces maturation of human monocyte-derived dendritic cells. J. Immunol. 175 (2005), 2974–2981.
64. 64 Hsu, Y.L., et al. Up-regulation of galectin-9 induces cell migration in human dendritic cells infected with dengue virus. J. Cell. Mol. Med. 19 (2015), 1065–1076.
65. 65 Nagahara, K., et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J. Immunol. 181 (2008), 7660–7669.
66. 66 Rabinovich, G.A., et al. Evidence of a role for galectin-1 in acute inflammation. Eur. J. Immunol. 30 (2000), 1331–1339.
67. 67 Woidacki, K., et al. Mast cells rescue implantation defects caused by c-kit deficiency. Cell Death Dis., 4, 2013, e462.
68. 68 Chen, H.Y., et al. Role of galectin-3 in mast cell functions: galectin-3-deficient mast cells exhibit impaired mediator release and defective JNK expression. J. Immunol. 177 (2006), 4991–4997.
69. 69 Bambouskova, M., et al. New regulatory roles of galectin-3 in high-affinity IgE receptor signaling. Mol. Cell. Biol. 36 (2016), 1366–1382.
70. 70 Kojima, R., et al. Galectin-9 enhances cytokine secretion, but suppresses survival and degranulation, in human mast cell line. PLoS ONE, 9, 2014, e86106.
71. 71 Ge, X.N., et al. Regulation of eosinophilia and allergic airway inflammation by the glycan-binding protein galectin-1. Proc. Natl. Acad. Sci. U.S.A. 113 (2016), 4837–4846.
72. 72 Mello, C.B., et al. Immunomodulatory effects of galectin-1 on an IgE-mediated allergic conjunctivitis model. Invest. Ophthalmol. Vis. Sci. 56 (2015), 693–704.
73. 73 Rao, S.P., et al. Galectin-3 functions as an adhesion molecule to support eosinophil rolling and adhesion under conditions of flow. J. Immunol. 179 (2007), 7800–7807.
74. 74 Matsushita, N., et al. Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. J. Biol. Chem. 275 (2000), 8355–8360.
75. 75 Chua, J.C., et al. Galectin-10, a potential biomarker of eosinophilic airway inflammation. PLoS ONE, 7, 2012, e42549.
76. 76 Young, A.R., et al. Functional characterization of an eosinophil-specific galectin, ovine galectin-14. Glycoconj. J. 26 (2009), 423–432.
77. 77 Cooper, D., et al. Novel insights into the inhibitory effects of Galectin-1 on neutrophil recruitment under flow. J. Leukoc. Biol. 83 (2008), 1459–1466.
78. 78 Auvynet, C., et al. Galectin-1 promotes human neutrophil migration. Glycobiology 23 (2013), 32–42.
79. 79 Stowell, S.R., et al. Galectin-1 induces reversible phosphatidylserine exposure at the plasma membrane. Mol. Biol. Cell 20 (2009), 1408–1418.
80. 80 Stowell, S.R., et al. Human galectin-1,-2, and -4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cells. Blood 109 (2007), 219–227.
81. 81 Nieminen, J., et al. Galectin-3 interacts with naive and primed neutrophils, inducing innate immune responses. J. Leukoc. Biol. 78 (2005), 1127–1135.
82. 82 Nieminen, J., et al. Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J. Biol. Chem. 282 (2007), 1374–1383.
83. 83 Bhaumik, P., et al. Galectin-3 facilitates neutrophil recruitment as an innate immune response to a parasitic protozoa cutaneous infection. J. Immunol. 190 (2013), 630–640.
84. 84 Mishra, B.B., et al. Galectin-3 functions as an alarmin: pathogenic role for sepsis development in murine respiratory tularemia. PLoS ONE, 8, 2013, e59616.
85. 85 Fernandez, G.C., et al. Galectin-3 and soluble fibrinogen act in concert to modulate neutrophil activation and survival: involvement of alternative MAPK pathways. Glycobiology 15 (2005), 519–527.
86. 86 Nishi, N., et al. Galectin-8 modulates neutrophil function via interaction with integrin alphaM. Glycobiology 13 (2003), 755–763.
87. 87 Vega-Carrascal, I., et al. Galectin-9 signaling through TIM-3 is involved in neutrophil-mediated Gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung. J. Immunol. 192 (2014), 2418–2431.
88. 88 Stowell, S.R., et al. Innate immune lectins kill bacteria expressing blood group antigen. Nat. Med. 16 (2010), 295–301.
89. 89 Croci, D.O., et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J. Exp. Med. 209 (2012), 1985–2000.
90. 90 Baker, G.J., et al. Natural killer cells require monocytic Gr–1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells. Oncoimmunology, 5, 2016, e1163461.
91. 91 Wang, W., et al. Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack. J. Biol. Chem. 289 (2014), 33311–33319.
92. 92 Tsuboi, S., et al. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J. 30 (2011), 3173–3185.
93. 93 Gleason, M.K., et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 119 (2012), 3064–3072.
94. 94 Golden-Mason, L., et al. Galectin-9 functionally impairs natural killer cells in humans and mice. J. Virol. 87 (2013), 4835–4845.
95. 95 Gauthier, L., et al. Galectin-1 is a stromal cell ligand of the pre-B cell receptor (BCR) implicated in synapse formation between pre-B and stromal cells and in pre-BCR triggering. Proc. Natl. Acad. Sci. U.S.A. 99 (2002), 13014–13019.
96. 96 Espeli, M., et al. Impaired B-cell development at the pre-BII-cell stage in galectin-1-deficient mice due to inefficient pre-BII/stromal cell interactions. Blood 113 (2009), 5878–5886.
97. 97 Elantak, L., et al. Structural basis for galectin-1-dependent pre-B cell receptor (pre-BCR) activation. J. Biol. Chem. 287 (2012), 44703–44713.
98. 98 Croci, D.O., et al. Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1. Leukemia 27 (2013), 1413–1416.
99. 99 Tsai, C.M., et al. Phosphoproteomic analyses reveal that galectin-1 augments the dynamics of B-cell receptor signaling. J. Proteomics 103 (2014), 241–253.
100. 100 Clark, M.C., et al. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 120 (2012), 4635–4644.
101. 101 Zuñiga, E., et al. Regulated expression of galectin-1 during B-cell activation and implications for T-cell apoptosis. J. Leukoc. Biol. 70 (2001), 73–79.
102. 102 Acosta-Rodriguez, E.V., et al. Galectin-3 mediates IL-4-induced survival and differentiation of B cells: functional cross-talk and implications during Trypanosoma cruzi infection. J. Immunol. 172 (2004), 493–502.
103. 103 Tabrizi, S.J., et al. T cell leukemia/lymphoma 1 and galectin-1 regulate survival/cell death pathways in human naive and IgM+ memory B cells through altering balances in Bcl-2 family proteins. J. Immunol. 182 (2009), 1490–1499.
104. 104 Anginot, A., et al. Galectin 1 modulates plasma cell homeostasis and regulates the humoral immune response. J. Immunol. 190 (2013), 5526–5533.
105. 105 Moritoki, M., et al. Galectin-9 ameliorates clinical severity of MRL/lpr lupus-prone mice by inducing plasma cell apoptosis independently of Tim-3. PLoS ONE, 8, 2013, e60807.
106. 106 Chen, I.J., et al. Lateral compartmentalization of T cell receptor versus CD45 by galectin-N-glycan binding and microfilaments coordinate basal and activation signaling. J. Biol. Chem. 48 (2007), 35361–35372.
107. 107 Demotte, N., et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 28 (2008), 414–424.
108. 108 Antonopoulos, A., et al. Loss of effector function of human cytolytic T lymphocytes is accompanied by major alterations in N- and O-glycosylation. J. Biol. Chem. 287 (2012), 11240–11251.
109. 109 Petit, A.E., et al. A major secretory defect of tumour-infiltrating T lymphocytes due to galectin impairing LFA-1-mediated synapse completion. Nat. Commun., 7, 2016, 12242.
110. 110 Mycko, M.P., et al. Brain glycolipids suppress T helper cells and inhibit autoimmune demyelination. J. Neurosci. 34 (2014), 8646–8658.
111. 111 Bi, S., et al. Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 10650–10655.
112. 112 Chen, H.Y., et al. Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 14496–14501.
113. 113 Madireddi, S., et al. Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. J. Exp. Med. 211 (2014), 1433–1448.
114. 114 de la Fuente, H., et al. The leukocyte activation receptor CD69 controls T cell differentiation through its interaction with galectin-1. Mol. Cell. Biol. 34 (2014), 2479–2487.
115. 115 Lichtenstein, R.G., Rabinovich, G.A., Glycobiology of cell death: when glycans and lectins govern cell fate. Cell Death Differ. 20 (2013), 976–986.
116. 116 Stillman, B.N., et al. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J. Immunol. 176 (2006), 778–789.
117. 117 Matarrese, P., et al. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J. Biol. Chem. 280 (2005), 6969–6985.
118. 118 Di Lella, S., et al. When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry 50 (2011), 7842–7857.
119. 119 Toscano, M.A., et al. Differential glycosylation of Th1, Th2 and Th-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 8 (2007), 825–834.
120. 120 Rabinovich, G.A., et al. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J. Exp. Med. 190 (1999), 385–398.
121. 121 Toscano, M.A., et al. Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J. Immunol. 176 (2006), 6323–6332.
122. 122 Banh, A., et al. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res. 71 (2011), 4423–4431.
123. 123 Juszczynski, P., et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 13134–13139.
124. 124 Dalotto-Moreno, T., et al. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res. 73 (2013), 1107–1117.
125. 125 Rubinstein, N., et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5 (2004), 241–251.
126. 126 Cedeno-Laurent, F., et al. Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood 119 (2012), 3534–3538.
127. 127 Cedeno-Laurent, F., et al. Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. J. Invest. Dermatol. 132 (2012), 410–420.
128. 128 Fukumori, T., et al. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res. 63 (2003), 8302–8311.
129. 129 Yang, R.Y., et al. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 13 (1996), 6737–6742.
130. 130 Deak, M., et al. Novel role for galectin-1 in T-cells under physiological and pathological conditions. Immunobiology 220 (2015), 483–489.
131. 131 Norambuena, A., et al. Galectin-8 induces apoptosis in Jurkat T cells by phosphatidic acid-mediated ERK1/2 activation supported by protein kinase A down-regulation. J. Biol. Chem. 284 (2009), 12670–12679.
132. 132 Tribulatti, M.V., et al. Galectin-8 induces apoptosis in the CD4(high)CD8(high) thymocyte subpopulation. Glycobiology 17 (2007), 1404–1412.
133. 133 Paclik, D., et al. Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. PLoS ONE, 3, 2008, e2629.
134. 134 Su, E.W., et al. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology 21 (2011), 1258–1265.
135. 135 Oomizu, S., et al. Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. Clin. Immunol. 143 (2012), 51–58.
136. 136 Li, Y., et al. The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity. Mol. Immunol. 48 (2011), 670–677.
137. 137 Jiang, H.R., et al. Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J. Immunol. 182 (2009), 1167–1173.
138. 138 Fermino, M.L., et al. Galectin-3 negatively regulates the frequency and function of CD4(+) CD25(+) Foxp3(+) regulatory T cells and influences the course of Leishmania major infection. Eur. J. Immunol. 43 (2013), 1806–1817.
139. 139 Sampson, J.F., et al. Galectin-8 promotes regulatory T-cell differentiation by modulating IL-2 and TGFbeta signaling. Immunol. Cell Biol., 94, 2016, 220.
140. 140 Wu, C., et al. Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity 41 (2014), 270–282.
141. 141 Cedeno-Laurent, F., et al. Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J. Immunol. 188 (2012), 3127–3137.
142. 142 Garin, M.I., et al. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 109 (2007), 2058–2065.
143. 143 Kubach, J., et al. Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood 110 (2007), 1550–1558.
144. 144 Wang, J., et al. Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in suppressing experimental autoimmune encephalomyelitis. J. Immunol. 182 (2009), 4036–4045.
145. 145 Rutkowski, M.R., et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27 (2015), 27–40.
146. 146 Bergers, G., Hanahan, D., Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8 (2008), 592–603.
147. 147 Thijssen, V.L., et al. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 70 (2010), 6216–6224.
148. 148 Laderach, D.J., et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res. 73 (2013), 86–96.
149. 149 Markowska, A.I., et al. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J. Exp. Med. 207 (2010), 1981–1993.
150. 150 Delgado, V.M., et al. Modulation of endothelial cell migration and angiogenesis: a novel function for the ‘tandem-repeat’ lectin galectin-8. FASEB J. 25 (2011), 242–254.
151. 151 Mathieu, V., et al. Galectin-1 in melanoma biology and related neo-angiogenesis processes. J. Invest. Dermatol. 132 (2012), 2245–2254.
152. 152 Baston, J.I., et al. Targeting galectin-1-induced angiogenesis mitigates the severity of endometriosis. J. Pathol. 234 (2014), 329–337.
153. 153 Hsieh, S.H., et al. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene 27 (2008), 3746–3753.
154. 154 D'Haene, N., et al. VEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin-3-induced angiogenesis. PLoS ONE, 8, 2013, e67029.
155. 155 Nangia-Makker, P., et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am. J. Pathol. 156 (2000), 899–909.
156. 156 Heusschen, R., et al. Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis. Biochim. Biophys. Acta 1842 (2014), 284–292.
157. 157 Vasta, G.R., Roles of galectins in infection. Nat. Rev. Microbiol. 7 (2009), 424–438.
158. 158 Mariño, K., et al. A systematic approach to protein glycosylation analysis: a path through the maze. Nat. Chem. Biol. 6 (2010), 713–723.
159. 159 Gabius, H.J., et al. From lectin structure to functional glycomics: principles of the sugar code. Trends Biochem. Sci. 36 (2011), 298–313.
160. 160 Yang, Z., et al. Engineered CHO cells for production of diverse, homogeneous glycoproteins. Nat. Biotechnol. 33 (2015), 842–844.
161. 161 Stanley, P., What have we learned from glycosyltransferase knockouts in mice?. J. Mol. Biol. 428 (2016), 3166–3182.
162. 162 Thiemann, S., Baum, L.G., Galectins and immune responses-just how do they do those things they do?. Annu. Rev. Immunol. 34 (2016), 243–264.
163. 163 Rabinovich, G., et al. Regulated expression of a 16-kd galectin-like protein in activated rat macrophages. J. Leukoc. Biol. 59 (1996), 363–370.
164. 164 Sato, S., Hughes, R.C., Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. J. Biol. Chem. 269 (1994), 4424–4430.
165. 165 Thijssen, V.L., et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. U.S.A. 103 (2006), 15975–15980.
166. 166 Etulain, J., et al. Control of angiogenesis by galectins involves the release of platelet-derived proangiogenic factors. PLoS ONE, 9, 2014, e96402.
167. 167 Thijssen, V.L., et al. The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am. J. Pathol. 172 (2008), 545–553.